Seagen and astellas announce presentation of results from padcev® (enfortumab vedotin-ejfv) pivotal trial in patients with previously treated advanced urothelial cancer who were ineligible for cisplatin chemotherapy

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq:sgen) and astellas pharma inc. (tse: 4503, president and ceo: kenji yasukawa, ph.d., “astellas”) today announced results from the second cohort (cohort 2) of patients in the pivotal phase 2 single-arm ev-201 trial. in the trial, 52 percent of patients who received padcev® (enfortumab vedotin-ejfv) had an objective response (95 percent confidence interval [ci]: 40.8, 62.4) and the median duration of response was 10.9 months (95 percent
SGEN Ratings Summary
SGEN Quant Ranking